Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents.
about
Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American CoReview of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?Endocannabinoids control platelet activation and limit aggregate formation under flowA review of the mechanisms and effectiveness of dietary polyphenols in reducing oxidative stress and thrombotic riskPrevalence of Thrombocytopenia and Its Association with Serum Magnesium.A randomised controlled trial comparing a dietary antiplatelet, the water-soluble tomato extract Fruitflow, with 75 mg aspirin in healthy subjectsActivated platelets from diabetic rats cause endothelial dysfunction by decreasing Akt/endothelial NO synthase signaling pathwayFruitflow®: the first European Food Safety Authority-approved natural cardio-protective functional ingredient.Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview.Increased Benefit With Vorapaxar Use in Patients With a History of Myocardial Infarction and Diabetes Mellitus: What the Data Show Us.Effects of outdoor air pollutants on platelet activation in people with type 2 diabetes.Influence of mental stress on platelet bioactivity.Study of platelet aggregation in acute coronary syndrome with special reference to metabolic syndromePlatelet perturbations in diabetes: implications for cardiovascular disease risk and treatment.New single-nucleotide polymorphisms associated with differences in platelet reactivity and their influence on survival in patients with type 2 diabetes treated with acetylsalicylic acid: an observational study.Effect of omega-3 fish oil on cardiovascular risk in diabetes.Variability of clopidogrel response in patients with type 2 diabetes mellitus.Antithrombotic therapy in patients with acute coronary syndrome and diabetes mellitus.Aspirin for primary prevention of cardiovascular disease events.Dual antiplatelet therapy in patients with diabetes mellitus: special considerations.Decreased platelet aggregation by shear stress-stimulated endothelial cells in vitro: description of a method and first results in diabetes.Ca2+ leakage rate from agonist-sensitive intracellular pools is altered in platelets from patients with type 2 diabetes.Will the epidemic of metabolic syndrome raise the prevalence of antiplatelet drug resistance?Platelets of type 2 diabetic patients are characterized by high ATP content and low mitochondrial membrane potential.Protective effect of metformin against retinal vein occlusions in diabetes mellitus - A nationwide population-based study.Evaluation of aspirin use in patients with diabetes receiving care in community health.Vascular Cognitive Impairment Linked to Brain Endothelium Inflammation in Early Stages of Heart Failure in Mice.Effect of a New Antioxidant Enoxifol on Platelet Aggregation and Blood Rheological Properties in Rats with Experimental Diabetes Mellitus.
P2860
Q22241289-528BF20F-05FB-48D6-BBB2-224409B2544BQ22241777-34A79531-FF19-42D3-B059-E61707657645Q27345221-C2AF615C-858D-426B-AD76-B68A33F2B8B7Q28301541-DB9B7AE4-6B0E-4CA1-B36E-D28F654F34DBQ33423721-10FACAEE-53DC-429E-A933-44B3D976532AQ33795282-8D6B636D-157A-4EFF-A7D6-6CDD10BBAD47Q33927945-9A083198-1E2A-47CA-85C4-C181435D60B1Q34533314-ADED5802-F1AD-4A57-9773-25AB013446FCQ35141772-769D6842-1A28-4E2C-B348-AA5B0763995EQ36094523-DE34901A-7EE9-438C-922E-7E6B9D69AEFCQ36919654-91313C58-DA1A-4296-B715-D137A8C4FE3FQ37195332-7869F22B-F432-4ADF-A829-A5C8EF61C4FAQ37198893-C799E761-2275-4A54-A5B2-9580ACD3E350Q37472064-6E883BCE-9FA9-4BD8-B54F-C8CF2CADF466Q37703289-72457414-C293-43C2-962F-A2818003C4F0Q37763811-6AE0C479-4D3E-416B-9D1E-94BD7FD5ECACQ37936014-DCCA4829-554F-44DA-A913-1CED20080C02Q37997963-4C88C89D-5FAE-4F31-9D57-F2DA5932088DQ38047265-46A24D64-6235-468E-9F0F-FED0B882C2B5Q38087381-B3885762-25FD-4AEA-8E63-D439F56A63C0Q39107339-7BDC9E7E-8056-4AF2-8BDB-558846B798FDQ39551541-B5B1EA20-656B-4650-8AE5-5EB1D2D8972FQ41910620-7A46D20E-1B20-45D3-96A5-20910BB349BEQ43260146-EAC9A90C-2D48-4605-B81F-61E33DEC65C1Q46230278-D0D5F48F-8B4E-4CFA-8BE9-ACFD7E02FF79Q51045941-1A8ABCDA-CAE4-4BA6-B184-3B6B32EEB9D8Q52629646-55059BA7-76A4-4162-AFCB-8D1B6703A8CEQ54025456-AC303663-EA34-40AB-9716-868FE6A05C6B
P2860
Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents.
@en
Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents.
@nl
type
label
Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents.
@en
Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents.
@nl
prefLabel
Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents.
@en
Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents.
@nl
P2093
P2860
P356
P1476
Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents.
@en
P2093
Arun Natarajan
Azfar G Zaman
Sally M Marshall
P2860
P304
P356
10.3132/DVDR.2008.023
P407
P577
2008-06-01T00:00:00Z